Risk-scoring system for predicting mucositis in patients of head and neck cancer receiving concurrent chemoradiotherapy [rssm-hn]
Background: One of the most distressing complications of head and neck cancer patients on chemoradiotherapy is mucositis. There is no proper tool to predict its occurrence in these patients. Aim: This study was conducted to develop a risk-scoring system to predict probable incidence and severity of...
Gespeichert in:
Veröffentlicht in: | Journal of cancer research and therapeutics 2011-03, Vol.6 (4) |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background: One of the most distressing complications of head and neck
cancer patients on chemoradiotherapy is mucositis. There is no proper
tool to predict its occurrence in these patients. Aim: This study was
conducted to develop a risk-scoring system to predict probable
incidence and severity of mucositis in head and neck cancer patients on
chemoradiotherapy. Materials and Methods: This is a retrospective
analysis conducted at a tertiary care cancer center with approximately
2,000 new cases of head and neck cancer patients annually. We
Hypothesized were age, comorbid conditions, leukocyte count,
nutritional status, oral hygiene, tobacco use, erythrocyte
sedimentation rate (ESR); Eastern cooperative oncology group (ECOG)
performance status (PS) and TNM (tumor, node, metastasis) stage as
possible risk factors. Receiver operating characteristic (ROC) curves
were drawn to predict the cutoff values for risk factors, and a final
scoring system was developed with sensitivity and specificity data.
Results: A total of 218 patients on chemoradiation receiving cisplatin
40 mg/m 2 /week along with local radiation of 60-70 Gy depending on
primary site were analyzed. Based on ROC analysis, the following cutoff
values were selected: age > 40 years, ECOG PS > 2, WBC <
3000/μL, elevated ESR, albumin < 3 gm/dL and > stage III
disease. The remaining factors were indicated as present or absent. A
score of 1 was assigned for the above risk factors. For patients, the
final score of 3 or less there is 17% probability of developing grade 3
or 4 mucositis, while patients having score of 6 or more have 76%
probability. Conclusion: The current tool is fairly accurate in
predicting development of mucositis in head and neck caner patients on
chemoradiotherapy. This will further help clinicians to adopt
preventive strategies as well as better counseling. |
---|---|
ISSN: | 0973-1482 |